Cyclopenthiazid

Bezeichnung:Cyclopenthiazid

CAS-Nr742-20-1

Englisch Name:Cyclopenthiazide

CBNumberCB1295254

SummenformelC13H18ClN3O4S2

Molgewicht379.88

MOL-Datei742-20-1.mol

Synonyma

Cyclopenthiazid

Cyclopenthiazid physikalisch-chemischer Eigenschaften

Schmelzpunkt	230°
Siedepunkt	605.6±65.0 °C(Predicted)
Dichte	1.3650 (rough estimate)
Brechungsindex	1.6100 (estimate)
storage temp.	Refrigerator
Löslichkeit	Acetonitrile (Slightly), DMSO (Slightly), Methanol (Sparingly)
Aggregatzustand	Solid
pka	9.00±0.40(Predicted)
Farbe	White to Off-White
Wasserlöslichkeit	50mg/L(room temperature)
CAS Datenbank	742-20-1(CAS DataBase Reference)
EPA chemische Informationen	2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-, 1,1-dioxide (742-20-1)

Sicherheit

Toxizität

LD50 in rats, mice (mg/kg): 141.8 ±24, 232.4 ±25 i.v. (Barrett)

Gefahreninformationscode (GHS)

Cyclopenthiazide Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Antihypertensive;Sodium Chloride Symporter Inhibitor
Verwenden
Cyclopenthiazide is a thiazide diuretic. Cyclopenthiazide is used in the treatment of oedema caused by conditions such as kidney disease, liver cirrhosis and pre-menstrual syndrome as well as in the treatment of hypertension.
Definition
ChEBI: 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide is a benzothiadiazine.
Weltgesundheitsorganisation (WHO)
Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It continues to be used mainly in combination drugs.
Clinical Use
Thiazide diuretic:
Hypertension

Heart failure

Oedema
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
Antibacterials: avoid administration with lymecycline.
Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
Antiepileptics: increased risk of hyponatraemia with carbamazepine.
Antifungals: increased risk of hypokalaemia with amphotericin.
Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide - avoid.
Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia occurs.
Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia.
Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
Lithium: excretion reduced, increased toxicity
Stoffwechsel
Cyclopenthiazide appears to be entirely excreted unchanged in the urine.

Cyclopenthiazid Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

742-20-1, Cyclopenthiazide Verwandte Suche:

Send Inquriy